Oryzon Genomics S.A. (BME:ORY)
Spain · Delayed Price · Currency is EUR 2.820
-0.020 (-0.70%)
Aug 27, 2026, 5:35 PM CET
Oryzon Genomics Revenue
In the year 2025, Oryzon Genomics had annual revenue of 11.67M EUR with 54.17% growth.
Revenue
11.67M
Revenue Growth
+54.17%
P/S Ratio
15.00
Revenue / Employee
334.94K
Employees
46
Market Cap
231.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.67M | 4.10M | 54.17% |
| Dec 31, 2024 | 7.57M | -6.77M | -47.22% |
| Dec 31, 2023 | 14.35M | -1.61M | -10.08% |
| Dec 31, 2022 | 15.95M | 5.17M | 47.95% |
| Dec 31, 2021 | 10.78M | 1.16M | 12.08% |
| Dec 31, 2020 | 9.62M | -691.16K | -6.70% |
| Dec 31, 2019 | 10.31M | 3.17M | 44.39% |
| Dec 31, 2018 | 7.14M | 2.41M | 50.80% |
| Dec 31, 2017 | 4.74M | -650.98K | -12.08% |
| Dec 31, 2016 | 5.39M | 1.11M | 25.87% |
| Dec 31, 2015 | 4.28M | -12.13M | -73.92% |
| Dec 31, 2014 | 16.41M | 13.32M | 430.92% |
| Dec 31, 2013 | 3.09M | -2.01M | -39.36% |
| Dec 31, 2012 | 5.10M | -877.65K | -14.69% |
| Dec 31, 2011 | 5.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.42B |
| Almirall | 1.16B |
| Laboratorios Farmaceuticos Rovi | 773.05M |
| Laboratorio Reig Jofre | 337.73M |
| Clínica Baviera | 320.67M |
| Prim, S.A. | 250.65M |
| Pharma Mar | 218.64M |
| Atrys Health | 144.31M |
Oryzon Genomics News
- 4 weeks ago - Oryzon Genomics Earnings release: Q2 2026 - Filings
- 3 months ago - Oryzon Genomics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026 - GlobeNewsWire
- 3 months ago - Oryzon Genomics Earnings release: Q1 2026 - Filings
- 3 months ago - ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026 - GlobeNewsWire
- 6 months ago - Oryzon Genomics announces patent grant decision in Mexico - TheFly
- 6 months ago - Oryzon Genomics Slides: Corporate presentation - Filings
- 6 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025 - GlobeNewsWire